Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie

Sylvie Lorenzen(Technical University of Munich), Florian Lordick(Leipzig University), Dirk Arnold(Asklepios Klinik Altona), Tibor Schuster(Technical University of Munich), Nadine Röthling(University Medical Center Freiburg), Rainer Porschen(Klinikum Bremen-Mitte), Markus Moehler(Johannes Gutenberg University Mainz), C. Peschel, Ralf‐Dieter Hofheinz(University of Mannheim), Tim F. Greten(National Cancer Institute), Peter Thuss‐Patience(Charité - Universitätsmedizin Berlin), L. Müller, Rupert Langer(Johannes Kepler University of Linz), S. Al-Batran(Krankenhaus Nordwest), Patricia Grabowski(Franklin University)
Annals of Oncology
June 24, 2009
10.1093/annonc/mdp069
Cited by 241

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
|Science|2017|6.6k
Gastric cancer
|The Lancet|2020|4.8k
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
|The Lancet|2019|2.6k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k